Literature DB >> 19956467

Open-label trial of acamprosate as a treatment for anxiety.

Marc Hertzman1, Ivy S Patt, Lisa A Spielman.   

Abstract

Entities:  

Year:  2009        PMID： 19956467      PMCID： PMC2781041          DOI： 10.4088/PCC.08l00714

Source DB:  PubMed          Journal:  Prim Care Companion J Clin Psychiatry        ISSN： 1523-5998


× No keyword cloud information.
  5 in total

1.  The assessment of anxiety states by rating.

Authors:  M HAMILTON
Journal:  Br J Med Psychol       Date:  1959

2.  A rating instrument for anxiety disorders.

Authors:  W W Zung
Journal:  Psychosomatics       Date:  1971 Nov-Dec       Impact factor: 2.386

3.  The pharmacological profile of glutamate-evoked ascorbic acid efflux measured by in vivo electrochemistry.

Authors:  J Cammack; B Ghasemzadeh; R N Adams
Journal:  Brain Res       Date:  1991-11-22       Impact factor: 3.252

4.  Pharmacological relapse prevention of alcoholism: clinical predictors of outcome.

Authors:  Falk Kiefer; Hauke Helwig; Timo Tarnaske; Christian Otte; Holger Jahn; Klaus Wiedemann
Journal:  Eur Addict Res       Date:  2005       Impact factor: 3.015

5.  Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients.

Authors:  Roel Verheul; Philippe Lehert; Peter J Geerlings; Maarten W J Koeter; Wim van den Brink
Journal:  Psychopharmacology (Berl)       Date:  2004-08-19       Impact factor: 4.530
  5 in total
  2 in total

Review 1.  Are Alcohol Anti-relapsing and Alcohol Withdrawal Drugs Useful in Cannabinoid Users?

Authors:  Patrycja Kleczkowska; Irena Smaga; Małgorzata Filip; Magdalena Bujalska-Zadrozny
Journal:  Neurotox Res       Date:  2016-08-02       Impact factor: 3.911

Review 2.  Acamprosate: A Review of Its Use in Alcohol Dependence.

Authors:  Greg L Plosker
Journal:  Drugs       Date:  2015-07       Impact factor: 9.546
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.